Resource Type

Journal Article 607

Conference Videos 6

Year

2024 3

2023 33

2022 49

2021 65

2020 38

2019 56

2018 40

2017 44

2016 28

2015 31

2014 27

2013 32

2012 25

2011 22

2010 16

2009 31

2008 16

2007 20

2006 4

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 8

solar cell 6

control 5

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

prognosis 5

stem cell 5

COVID-19 4

SARS-CoV-2 4

cell proliferation 4

lung cancer 4

microbial fuel cell 4

solid oxide fuel cell 4

High pressure 3

cancer immunotherapy 3

chemotherapy 3

solid oxide fuel cell (SOFC) 3

open ︾

Search scope:

排序： Display mode:

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellcells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansioncell therapy.

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been wellsurvival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19 CAR-Tcell therapy.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tbearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TEpidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in variousThus, EGFRvIII is a potential antigen for targeted lung cancer therapy.cell lines.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyglycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation     O-glycans     adoptive cell therapy    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltratingCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughshematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cellThe clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited.Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodies, chimericantigen receptor T cell products, and cancer vaccines.Bispecific antibodies, which bind two different antigens or one antigen with two different epitopes,Chimeric antigen receptor T cell products and cancer vaccines have also been investigated.

Keywords： cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer    

HTML PDF Collect

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 160-184 doi: 10.1007/s11684-020-0750-4

Abstract: Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and safety have been genetically modified, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Keywords： immunotherapy     oncolytic virus     genetic modification     immune checkpoint blockade     chimeric antigen receptorT cell    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingAnti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalWe believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigensAt present, exciting results are being achieved in clinical applications of CAR-T cells for patientscell products are expected to be submitted in future.cell products based on their product characteristics and on relevant guidelines for gene and cell therapy

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Review

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Engineering 2022, Volume 10, Issue 3,   Pages 30-43 doi: 10.1016/j.eng.2021.10.018

Abstract:

Chimeric antigen receptors (CARs) are a breakthrough in genetic engineering that have revolutionizedCells expressing these receptors are rerouted to a predefined target by the inclusion of an antigen-specificIn contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressing

Keywords： Chimeric antigen receptors     T cell     Treg     Alloimmunity     Bioengineering     Transplant     Autoimmunity    

HTML PDF Collect

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Frontiers of Medicine 2019, Volume 13, Issue 5,   Pages 610-617 doi: 10.1007/s11684-019-0714-8

Abstract: Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely usedrefractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-TThe early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading and

Keywords： chimeric antigen receptor T cell     cytokine release syndrome     tocilizumab    

HTML PDF Collect

Title Author Date Type Operation

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

Emerging immunological strategies: recent advances and future directions

Journal Article

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Journal Article

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Journal Article